Invetx is a technology company.
Invetx has raised $86.0M across 3 funding rounds.
Invetx has raised $86.0M in total across 3 funding rounds.
Invetx has raised $86.0M in total across 3 funding rounds.
Invetx's investors include Anterra Capital, F-Prime Capital Partners.
Invetx is a biotechnology company developing novel protein-based therapeutics, particularly monoclonal antibodies (mAbs), to treat chronic and severe diseases in companion animals like dogs and cats. It leverages a fully integrated platform for discovery, development, and manufacturing, targeting conditions such as atopic dermatitis, osteoarthritis, pain, allergy, cancer, and diabetes to elevate veterinary care standards.[1][2][3][4] Founded in 2018 and headquartered in Boston, Massachusetts, Invetx raised $85.75M–$86M across funding rounds, including a $25.5M Series A in 2020 and a $60.5M later round, before being acquired by Dechra Pharmaceuticals in July 2024, where it now operates as a dedicated division.[1][2][3][5] This acquisition bolsters Dechra's pipeline with Invetx's species-specific, half-life extended mAbs that offer longer-lasting, convenient treatments for pet owners and veterinarians.[3][4]
Invetx was founded in 2018 by a team of R&D leaders with expertise from human biotech and animal health sectors, aiming to adapt advanced biopharmaceutical technologies for veterinary use.[2][4][5] The idea emerged from recognizing that companion animals, increasingly treated as family members with longer lifespans, needed targeted therapies like those in human medicine—highly effective, safe biotherapeutics to address chronic conditions without daily dosing burdens.[4] Early traction came via strategic partnerships with biotech firms like AbCellera Biologics for antibody discovery and WuXi Biologics for manufacturing platforms, plus a $25.5M Series A in 2020 from investors including Anterra Capital, Casdin Capital, Tekla Capital Management, and F-Prime Capital.[1][5] Investors like F-Prime provided deep biotech knowledge, supporting Invetx's growth into a pipeline leader until its pivotal acquisition by Dechra in July 2024.[1][3]
Invetx rides the surge in pet humanization, where growing global pet populations and owners' demands for advanced, human-like care fuel a high-growth animal health market, particularly for biologics like mAbs.[3][4] Its timing aligns with maturing biotech tools from human medicine—antibody discovery and manufacturing—now adapted for veterinary gaps, where chronic diseases in aging pets create unmet needs amid rising pet healthcare spending.[1][3] Market forces like Dechra's acquisition amplify this, providing commercial scale, synergistic portfolios, and entry into biologics, while influencing the ecosystem by pioneering convenient therapies that deepen expertise in dermatology and orthopedics, spurring innovation from rivals like Xeptiva and HIPRA.[2][3]
Post-acquisition, Invetx will advance its pipeline within Dechra, prioritizing commercialization of half-life extended mAbs for companion animal chronic conditions, leveraging Dechra's sales, marketing, and global reach for faster market entry.[3][4] Trends like expanding pet longevity, biologics adoption in vet med, and AI-enhanced discovery (echoed in sector parallels) will shape its path, potentially deepening synergies in high-value therapeutics.[2][3] Its influence may evolve from startup innovator to division leader, setting new care standards and inspiring cross-sector biotech transfers, ultimately transforming how pets live longer, healthier lives.
Invetx has raised $86.0M across 3 funding rounds. Most recently, it raised $61.0M Series B in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2022 | $61.0M Series B | Anterra Capital, F-Prime Capital Partners | |
| Sep 1, 2020 | $10.0M Series A | Anterra Capital | |
| Feb 1, 2020 | $15.0M Series A | Anterra Capital |